Stay updated on Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial
Sign up to get notified when there's something new on the Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial page.

Latest updates to the Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial page
- Check5 days agoChange DetectedThe page footer's revision tag was updated from v3.5.4 to v3.5.5, indicating a small update to the page’s revision history.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page now shows Revision: v3.5.4, replacing the previous Revision: v3.5.3. This reflects a small update to the documentation or underlying page/versioning system.SummaryDifference0.0%

- Check48 days agoChange DetectedThe page’s revision label was updated from **Revision: v3.5.2** to **Revision: v3.5.3**.SummaryDifference0.0%

- Check55 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check83 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3 from the page.SummaryDifference0.0%

- Check91 days agoChange DetectedDeleted the citation for Wei AH et al. on risk stratification of low-dose cytarabine and venetoclax in AML (Blood Advances, 2026).SummaryDifference0.0%

Stay in the know with updates to Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial page.